Q-omics provides the consensus-scored TP53TG1 profile across patient tissues and cancer cell-line models. TP53TG1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, TP53TG1 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, TP53TG1 RNA expression shows 17,645 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BRCA, COAD, and THYM as cancer lineages where TP53TG1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TP53TG1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TP53TG1 survival associations across molecular data types. TP53TG1 RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TP53TG1 RNA expression–survival associations across cancer types. High TP53TG1 expression shows unfavorable associations in STAD, KICH and KIRP, but favorable associations in BRCA, MESO and BLCA. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for TP53TG1 RNA expression.
This table summarizes TP53TG1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for TP53TG1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TP53TG1 shows lower tumor expression in COAD, KICH, STAD and UCEC and higher tumor expression in HNSC and KIRP. The COAD box plot shows higher TP53TG1 RNA expression in normal versus tumor tissue (log2 FC = −1.460, t-test p < 0.001).
This table shows molecular features associated with TP53TG1 in patient tissues and cancer cell lines. In patient samples, TP53TG1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, TP53TG1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in NCI60_ALL.
